Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience. Journal Abstract - Guideline Central

Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience.

Published: 2026 May 25

Authors

, , , , , , ,

Abstract

Background Cytomegalovirus (CMV) infection is a major contributor to morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT), solid organ transplant (SOT), and chimeric antigen receptor T-cell (CAR-T) therapy. While antiviral agents remain the cornerstone of treatment, CMV-specific immunoglobulins (CMVIG) have been utilized as adjunct therapy with variable outcomes. This study aims to evaluate the virological response and tolerability of CMVIG in cases of severe or refractory CMV viremia, with or without CMV disease.

Keywords: CMV immunoglobulin, Cytomegalovirus, and chimeric antigen receptor T-cell (CAR-T) therapy, hematopoietic stem cell transplant, solid organ transplant

Source

Viruses

Publication Type

Journal Article

Language

English

PubMed ID

42357610

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.